SkylineDx's Innovative Merlin Assay Significantly Reduces Sentinel Lymph Node Biopsies in Melanoma Patients SkylineDx's Merlin Assay demonstrates remarkable efficacy in reducing sentinel lymph node biopsies by over 40% in melanoma patients, enhancing treatment decision-making.

SkylineDx's Innovative Merlin Assay Significantly Reduces Sentinel Lymph Node Biopsies in Melanoma Patients #Netherlands #Rotterdam #SkylineDx #melanoma #Merlin_Assay

SkylineDx's Merlin CP-GEP Assay Shows High Predictive Accuracy for Patient Selection in Sentinel Lymph Node Biopsy A recent independent meta-analysis validates the efficacy of SkylineDx's Merlin CP-GEP assay, showing its ability to accurately assess patients' needs for sentinel lymph node biopsy in melanoma cases.

SkylineDx's Merlin CP-GEP Assay Shows High Predictive Accuracy for Patient Selection in Sentinel Lymph Node Biopsy #Netherlands #Rotterdam #SkylineDx #Merlin_Assay #CP-GEP

SkylineDx Unveils Mermaid Assay at ASCO 2025 to Revolutionize Melanoma Recurrence Predictions SkylineDx highlights the Merlin Assay's capability to predict recurrence risk in head and neck melanoma at the ASCO 2025 conference, supporting non-invasive approaches.

SkylineDx Unveils Mermaid Assay at ASCO 2025 to Revolutionize Melanoma Recurrence Predictions #Netherlands #Rotterdam #SkylineDx #melanoma #Merlin_Assay